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Type 1 interferon (IFN) suppresses viral replication by upregulating the expression of 17 
interferon-stimulated genes (ISGs) with diverse anti-viral properties1. The replication of 18 
human immunodeficiency virus type-1 (HIV-1) is naturally inhibited by IFN, with the steps 19 
between viral entry and chromosomal integration of viral DNA being notably susceptible2-5. 20 
The ISG myxovirus resistance 2 (MX2) has been defined as an effective post-entry inhibitor 21 
of HIV-1, but is only partially responsible for IFN’s suppressive effect6-8. Using siRNA-based 22 
library screening in IFNa-treated cells, we sought to characterize further ISGs that target 23 
the pre-integration phases of HIV-1 infection, and identified human tri-partite-containing 24 
motif 5a (TRIM5a) as a potent anti-HIV-1 restriction factor. Human TRIM5a, in contrast 25 
to many non-human orthologues, has not generally been ascribed significant HIV-1 26 
inhibitory function, a finding attributed to ineffective recognition of cytoplasmic viral 27 
capsids by TRIM5a2,9,10. Here, we demonstrate that IFNa-mediated stimulation of the 28 
immunoproteasome, a proteasome isoform mainly present in immune cells and distinguished 29 
from the constitutive proteasome by virtue of its different catalytic b-subunits as well as the 30 
proteasome activator (PA) 28 regulatory complex11-13, and the associated accelerated 31 
turnover of TRIM5a underpin the reprogramming of human TRIM5a for effective capsid-32 
dependent inhibition of HIV-1 DNA synthesis and infection. These observations identify a 33 
mechanism for regulating human TRIM5a anti-viral function in human cells and rationalize 34 
how TRIM5a participates in the immune control of HIV-1 infection.  35 
 36 
IFNa mobilizes the expression of hundreds of ISGs, with the functions and viral substrates of 37 
many awaiting definition1. To identify ISGs that suppress HIV-1 replication, we designed an 38 
siRNA library targeting 598 ISGs (plus two negative controls; Supplementary Table 1). Focusing 39 
on the early stages of infection (up to and including viral transcription), two cultures of IFNa-40 
responsive U87-MG CD4+ CXCR4+ cells were transfected with each siRNA, with one being 41 
maintained with 500 U ml-1 IFNa for 24 h and one without. All cultures were then challenged with 42 
HIV-1/Nef-internal ribosome entry signal (IRES)-Renilla, a modified replication-competent 43 
reporter virus, and infection quantified by measuring Renilla luciferase activity at 48 h (Fig. 1a; 44 
unadjusted levels of infection indicated in left hand panel, and folds of IFNa-mediated suppression 45 
indicated in right hand panel; Supplementary Fig. 1). Three genes of well-established relevance to 46 
HIV-1 infection and whose suppression corresponded with markedly increased levels of infection 47 
in the presence of IFNa were interferon regulatory factor 9 (IRF9), MX2 and TRIM5a 48 
(Supplementary Fig. 2 displays the 14 genes with the strongest effects). IRF9, a transcription factor 49 
required for ISG induction4, and MX2, an established HIV-1 inhibitory ISG6,7, were anticipated 50 
finds, but TRIM5a was completely unexpected. Indeed, human TRIM5a has hithertofore been 51 
regarded as being virtually inactive against HIV-1; in contrast, non-human TRIM5a proteins, for 52 
example from rhesus macaque, are potent HIV-1 restriction factors that recognize post-entry viral 53 
capsids to induce their premature fragmentation and the inhibition of reverse transcription2,9. 54 
 55 
The restorative impact of each component TRIM5a siRNA of the smartpool against IFNa 56 
suppressed HIV-1 infection was confirmed using a HIV-1/Nef-IRES-green fluorescent protein 57 
(GFP) reporter virus, with IFNa-mediated inhibition consistently decreasing by 2- to 4-fold 58 
relative to the non-silencing siControl (Fig. 1b) and TRIM5a expression being reliably silenced 59 
(Fig. 1c). Similar levels of rescue of infection were also observed in a bulk cell population and two 60 
independent knock-out cell lines in which the endogenous TRIM5a alleles had been inactivated 61 
using CRISPR-Cas9 genome editing (Fig. 1d and 1e; Supplementary Fig. 3); and across a range 62 
of IFNa doses (Supplementary Fig. 4). Importantly, re-introduction of a CRISPR-resistant human 63 
TRIM5a (rTRIM5a) cDNA into these cells completely restored IFNa-mediated suppression, 64 
while no changes in HIV-1 susceptibility were detected with an irrelevant control gene (luciferase) 65 
(Fig. 1f). shRNA-mediated silencing was then used to suppress TRIM5a expression in primary 66 
human CD4+ T cells. Relative to donor matched control samples, reducing TRIM5a levels 67 
significantly impeded the IFNa-mediated inhibition of HIV-1 infection, therefore confirming the 68 
importance of this IFNa-regulated anti-viral pathway in the principal in vivo cell target of HIV-1 69 
infection (Fig. 1g and Supplementary Fig. 5). As noted earlier, it has been established that IFNa 70 
is a potent and early inhibitor of HIV-1 reverse transcription following entry into susceptible cells3: 71 
TRIM5a’s substantial contribution to this effect was demonstrated by using quantitative PCR to 72 
measure the restoration of viral cDNA accumulation following TRIM5a silencing in IFNa treated 73 
cells (~5-fold rescue, Fig. 1h). The broad sensitivity of diverse strains to IFNa-activated human 74 
TRIM5a, was confirmed using siRNA-mediated silencing and ten HIV-1 isolates engineered to 75 
confer GFP expression following productive infection (extents of rescue ranging from 2- to 5-fold, 76 
Supplementary Fig. 6).  77 
 78 
TRIM5a-mediated inhibition is initiated through the recognition of viral capsids in the cytoplasm, 79 
leading to their fragmentation and the suppression of reverse transcription (viral DNA synthesis). 80 
Binding is both sequence- and structure-specific, and is dependent on the capsid lattice (which is 81 
composed of multiple hexagonal and pentagonal assemblies the viral Capsid (CA) protein)14 and 82 
the carboxy-terminal SPRY (a sequence repeat in dual-specificity kinase SPlA and RYanodine 83 
receptors) domain of TRIM5a2,9. The specificity of human TRIM5a for HIV-1 CA was 84 
demonstrated by the reduced inhibitory effect of IFNa following TRIM5a silencing that was seen 85 
for virus bearing wild-type HIV-1 CA (WTCA), but not for a matched HIV-1-based chimeric virus 86 
carrying (non-recognized) CA derived from a simian immunodeficiency virus (SIV) (SIVCA) (Fig. 87 
2a). The suppression of HIV-1 by human TRIM5a is not, therefore, the result of a generalized 88 
induction of TRIM5a anti-lentiviral activity by IFNa. 89 
 90 
The central importance of the SPRY domain for TRIM5a function in the presence of IFNa was 91 
then confirmed in gene transduction-based experiments using U87-MG CD4+ CXCR4+ cells where 92 
endogenous TRIM5a and MX2 expression were ablated using CRISPR-Cas9 genome editing (Fig. 93 
2b; Supplementary Fig. 7 and 8): luciferase and CD8 served as negative controls for not affecting 94 
infection (~5-fold suppression of infection in the presence of IFNa), whereas a previously defined 95 
TRIM-cyclophilin (TRIMCyp) fusion protein and MX2 were positive controls6,7,10 whose 96 
inhibitory phenotypes do not depend on IFNa (Fig. 2b). Consistent with our findings with the 97 
endogenous gene, ectopically expressed human TRIM5a inhibited HIV-1 infection very 98 
effectively when IFNa was added (total suppression of ~14-fold). Removing the SPRY domain 99 
abolished this effect (~5-fold suppression), whereas including mutations (R332G and R335G) that 100 
have previously been shown to confer anti-HIV-1 activity15,16 still did so to a minor extent and 101 
without compromising activation by IFNa (~14-fold total suppression).  102 
 103 
TRIM5a is an E3 ubiquitin (Ub) ligase that is polyubiquitinated by cellular E2 Ub conjugating 104 
enzymes as a pre-requisite for suppressing reverse transcription and infection17-19. Consistent with 105 
previous results20, the integrity of TRIM5a’s ligase domain was confirmed as being necessary for 106 
viral inhibition through its inactivation by the H43Y mutation (Fig. 2b). Next, to determine the 107 
effects of IFNa on TRIM5a ubiquitination and ensuing proteasome-mediated degradation, cells 108 
were co-transfected with vectors expressing FLAG-tagged TRIM5a and HA-tagged Ub, and 109 
whole cell lysates or immunoprecipitated FLAG-tagged proteins analyzed by immunoblotting 110 
(Fig. 3a). IFNa did not substantially affect global levels of protein ubiquitination (lanes 1 to 8), 111 
but did induce a marked decrease in the level of ubiquitinated TRIM5a (lanes 10 and 14). This 112 
decrease was reversed by addition of the broadly acting proteasome inhibitor MG132 or the 113 
immunoproteasome-specific inhibitor ONX-0914 (lanes 15 and 16, respectively).  114 
 115 
Confirmation that IFNa specifically promotes the proteolytic turnover of TRIM5a was obtained 116 
in three ways: first, analysis of cells co-expressing FLAG-tagged TRIM5a and FLAG-tagged GFP 117 
as a control showed that IFNa induced the marked loss of TRIM5a and that this was blocked by 118 
MG132 or ONX-0914 (Fig. 3b); second, levels of endogenous TRIM5a in IFNa treated cells were 119 
increased by adding MG132 or ONX-0914 (Fig. 3c; of note, because TRIM5a is an ISG itself its 120 
levels were modestly increased by IFNa addition compared to untreated cells21, despite its 121 
accelerated turnover); and third, metabolic-labelling and pulse-chase analysis of FLAG-TRIM5a 122 
in transfected cells demonstrated a shortening in initial half-life from ~100 min to ~70 min 123 
(Supplementary Fig. 9). As expected for proteasome-mediated degradation22, blocking the 124 
formation of lysine-48-linked polyubiquitin chains by co-expression of the K48R ubiquitin mutant 125 
inhibited IFNa-induced TRIM5a proteolysis (Supplementary Fig. 10).  126 
 127 
The importance of proteasomal activity for IFNa-mediated suppression was confirmed in viral 128 
challenge experiments, where both inhibitors significantly reversed the inhibitory influence of 129 
IFNa (~3-fold rescue, Fig. 3d; Supplementary Fig. 11). This effect was shown to be dependent on 130 
TRIM5a function since, in the presence of IFNa, HIV-1 infection of cells lacking endogenous 131 
TRIM5a was not improved by MG132 or ONX-0914 (Fig. 3e; Supplementary Fig. 12).  132 
 133 
The immunoproteasome is predominantly expressed in cells of haematopoietic origin in response 134 
to inflammatory cytokines such as IFN, and differs from the constitutive proteasome with respect 135 
to the identity of its three proteolytic b-subunits and dependence upon the PA28 regulatory 136 
complex11,12,23 (Fig. 4a). Its functional divergence from the constitutive proteasome is 137 
incompletely understood, though roles in MHC class I antigen processing, T cell differentiation 138 
and cytokine modulation have been described24,25. In light of the ability of ONX-0914, a selective 139 
inhibitor of b5i/PSMB8, to block IFNa-induced TRIM5a function (Fig. 3e), the expression 140 
patterns of the immunoproteasome b-subunits and the PA28A/PA28B subunits of the PA28 141 
regulatory complex were analyzed by immunoblotting (Fig. 4b). With some variation, all five 142 
proteins accumulated to higher levels in the presence of IFNa.  143 
 144 
These five immunoproteasome components, as well as TRIM5a, were then individually silenced 145 
using siRNA (Fig. 4b) and the effects on IFNa-induced viral suppression determined (Fig. 4c; 146 
Supplementary Fig. 13). All knock-downs conferred a degree of relief from inhibition by IFNa, 147 
with PA28A silencing being the most effective to the extent that the magnitude of rescue matched 148 
that observed with silencing of TRIM5a itself. Finally, the functional inter-dependence of the 149 
IFNa-activated anti-HIV-1 phenotypes of human TRIM5a and the immunoproteasome was 150 
established by the substantial diminution in the level of rescue from IFNa inhibition that was 151 
observed following PA28A silencing in cells that lacked TRIM5a (Fig. 4d; Supplementary Fig. 152 
14).  153 
 154 
TRIM5a restriction has been widely perceived to be important for preventing zoonotic retroviral 155 
infections, while being ineffective in controlling viruses in their natural hosts2,9. Though there have 156 
been sporadic reports of human TRIM5a affecting HIV-1 infection either by suppression of certain 157 
HLA-associated CTL escape mutant viruses26, or by inducing autophagy in Langerhans cells27, 158 
our findings demonstrate broad, non-strain specific inhibition of HIV-1 infection by human 159 
TRIM5a. Importantly, we have shown that TRIM5a function is operative in CD4+ T cells, and is 160 
dependent on IFNa and activation of the immunoproteasome. Given that IFN levels are elevated 161 
during the acute and chronic phases of natural HIV-1 infection4, we surmise that TRIM5a 162 
contributes to the immune control of HIV-1 in infected humans; a conclusion consistent with noted 163 
associations between favourable clinical outcomes and elevated TRIM5a expression28 or specific 164 
TRIM5a alleles29,30. Finally, these results further indicate that the functionality of a specific protein 165 
can be fine-tuned by the proteasomal landscape of a cell. 166 
 167 
 168 
Methods: 169 
HIV-1 molecular clones and retroviral vectors. The NL4-3/Nef-IRES-Renilla and NL4-3/Nef-170 
IRES-green fluorescent protein (GFP) reporter viruses, the HIV-1 based lentiviral vectors 171 
containing wild-type Capsid (WTCA) or CA from SIVMAC (SIVCA), and the infectious provirus 172 
molecular clones HIV-1 NL4.3, THRO, WITO, CH106.c, REJO.c, SUMA, pAD17, WARO, 173 
R66201 and IDU034.2 have been described31,32,33,34,35.  174 
 175 
Cells. U87-MG CD4+ CXCR4+ cells, which stably express the CD4 and CXCR4 receptors have 176 
been described6, and 293T cells were obtained from the American Type Culture Collection 177 
(ATCC). All cell lines were maintained in complete Dulbecco’s modified Eagle medium 178 
(DMEM)-GlutaMAX (Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco), 100 U 179 
ml-1 penicillin and 100 g ml-1 streptomycin. Human primary CD4+ T cells were isolated from 180 
peripheral blood mononuclear cells (PBMCs) of healthy donors (approved by the Guy’s Research 181 
Ethics Committee; Ref 03/02/06) obtained by density gradient centrifugation through LymphoPrep 182 
(Axis-Shield) and isolated by negative selection using the CD4+ T Cell Isolation Kit (Miltenyi 183 
Biotec) according to the manufacturer’s instructions. Cells were activated using Dynabeads 184 
Human T-Activator CD3/CD28 (ThermoFisher) and 50 U ml-1 recombinant IL-2 (rIL-2) (Roche) 185 
for 48 h in RPMI 1640-GlutaMAX medium containing 10% heat-inactivated autologous serum, 186 
100 U ml-1 penicillin and 100 U ml-1 streptomycin. Cells were maintained after activation in 187 
medium containing 30 U ml-1 of rIL-2. Cells were treated with IFNa-2b (INTRON A, Merck, 188 
Sharpe & Dohme Corp.) for 24 h prior to infection. U87-MG CD4+ CXCR4+ cells were treated 189 
with DMSO (Sigma), the proteasome inhibitor MG132 (0.2 µM, Abcam, ab141003) or the 190 
immunoproteasome inhibitor ONX-0914 (1 µM, ApexBio, A4011). 191 
 192 
siRNA library screen. To identify interferon stimulated genes (ISGs) that modulate HIV-1 193 
infection, we performed an ISGs siRNA screen using a custom siRNA library (Dharmacon) 194 
containing 600 siRNA targets (Supplementary Table 1). U87-MG CD4+ CXCR4+ cells were plated 195 
at 1.2 x 104 per well in a 96-well plate and were reverse transfected with siRNA (10 nM). 24 h 196 
later, cells were treated with or without IFNa (500 U ml-1) and, after 12 h incubation, a second 197 
siRNA transfection was performed. 24 h after IFNa treatment, cells were challenged with NL4-198 
3/Nef-IRES-Renilla (15 ng p24Gag) and infectivity was determined 48 h later by measuring Renilla 199 
activity. 200 
 201 
Plasmids. pEasiLV plasmids expressing luciferase, CD8, MX2 or TRIMCYP have been 202 
described6. cDNAs encoding TRIM5α and TRIM5α isoform X7 lacking the SPRY domain were 203 
amplified using the SuperScript III One-Step RT–PCR System with Platinum Taq polymerase 204 
(Invitrogen) from 20 ng RNA obtained from IFNa-treated (500 U ml-1) U87-MG CD4+ CXCR4+ 205 
cells and inserted into pEasiLV-MCS6 between the AgeI and XhoI restriction sites. The TRIM5α 206 
R332G/R335G and H43Y mutants were obtained by site directed mutagenesis (SDM). CRISPR-207 
resistant TRIM5α constructs (rTRIM5α) were produced by SDM using primers designed to 208 
silently mutate the guide RNA target sequence. pFLAG-TRIM5α was generated by subcloning a 209 
cDNA encoding TRIM5α with an N-terminal FLAG tag into pCAGGS (Addgene) using the EcoRI 210 
and XhoI sites. pCAGGS expressing FLAG-tagged GFP, pFLAG-GFP, was derived from a 211 
plasmid encoding HA-tagged GFP36. The vectors encoding HA-tagged ubiquitin and the K48R 212 
and K63R mutant derivatives have been described37 38.  213 
 214 
Knock-out cells. To generate CRISPR/Cas9 cells, sequences encoding specific guide RNAs 215 
targeting TRIM5α, MX2 or red fluorescent protein (RFP), as a control, were cloned into BsmBI-216 
linearized lentiviral vector pLentiCRISPRv239,40 using the oligonucleotides (forward/reverse) 5′-217 
caccgCCTCCTCCTTTACATTAACC-3′ and 5′-aaacGGTTAATGTAAAGGAGGAGGc-3′ for 218 
TRIM5α, (5′-caccgGACAACCAGCCCCGAGACAT-3′ and 5′-219 
aaacATGTCTCGGGGCTGGTTGTCc-3′) for MX2 or 5′-220 
caccgCTCAGTTCCAGTACGGCTCCA-3′ and 5′-aaacTGGAGCCGTACTGGAACTGAGc-3′ 221 
for RFP. Vectors expressing the indicated guide RNAs were produced by co-transfection of 293T 222 
cells with pLentiCRISPRv2, p8.91 and VSV-G vectors at a ratio of 1.5:1.5:0.375, respectively. 223 
U87-MG CD4+ CXCR4+ cells were transduced with the TRIM5α targeting or RFP control 224 
lentiviral vectors and selected using 1 μg ml−1 puromycin for three days. Single-cell clones 225 
(TRIM5α #1 and TRIM5α #2) were derived from the bulk (TRIM5α) population by single-cell 226 
sorting in 96-well plates and assayed for the loss of TRIM5α by immunoblotting. TRIM5α gene 227 
disruption was validated by PCR amplification and sequencing of the targeted genomic region. To 228 
generate TRIM5a/MX2 double knock-out cells, the TRIM5α #1 line (Fig. 1d) was further 229 
transduced with a high concentration of the MX2 targeting vector and the loss of MX2 expression 230 
in the bulk population was confirmed by immunoblotting.  231 
 232 
Viral production. All viruses were generated by transfection of 10 cm 293T cultures using 233 
TransIT-2020 transfection reagent (Mirus), the medium was changed after 6 h and virus containing 234 
medium was filtered and collected 48 h after transfection. NL4-3/Nef-IRES-GFP and NL4-3/Nef-235 
IRES-Renilla viral particles were produced by transfection of 10 µg of proviral plasmid. For 236 
analysis of HIV-1 reverse transcription products and shRNA-mediated TRIM5α silencing, virus 237 
containing supernatants were DNAse (RQ1 RNase free DNAse; Promega) treated for 1 h at 37 °C, 238 
and viruses were purified through a 20% (wt/vol) sucrose cushion at 145,370 × g for 75 min at 4 239 
°C, re-suspended in phosphate buffered saline (PBS) and stored in aliquots at -80 °C. Lentiviral 240 
vectors stocks were produced by co-transfection of 293T cells with plasmids encoding Gag-Pol 241 
(p8.91 or p8.91-SIVCA), a mini viral genome bearing a CMV-GFP expression cassette 242 
(pRRL.sin.cPPT.CMV/eGFP), and the VSV-G envelope (pMD.G), at a ratio of 4:4:2, 243 
respectively3. To generate GFP encoding derivatives of full-length molecular clones NL4.3, 244 
THRO, WITO, CH106.c, REJO.c, SUMA, pAD17, WARO, R66201 and IDU034.2 provirus 245 
plasmids were co-transfected with the GFP reporter vector pCSGW and VSV-G at a ratio of 246 
4.5:3:3, respectively41. Virus titers were determined by challenging U87-MG CD4+ CXCR4+ cells 247 
with different viral dilutions and by quantifying the number of GFP-positive cells after 48 h by 248 
flow cytometry (FACSCalibur; BD Biosciences) (a typical example is displayed in Supplementary 249 
Fig. 15), and p24Gag content was quantified using an HIV-1 p24 ELISA detection kit (Perkin-250 
Elmer). To produce EasiLV particles, 293T cells were co-transfected with pEasiLV, p8.91, 251 
pptTRKrab and VSV-G at a ratio of 1:1:0.5:0.25, respectively6. 48 h after transfection, viral 252 
particles were harvested, filtered, and used directly to transduce U87-MG CD4+ CXCR4+ cells. 6 253 
h after transduction, the medium was replaced with fresh medium containing 0.5 µg ml-1 254 
doxycycline (Sigma) to induce transgene expression. 72 h after transduction, the percentage of E2-255 
Crimson-positive cells was scored (typically >80%) by flow cytometry. 256 
 257 
shRNA-mediated TRIM5α silencing. TRIM5α silencing in primary human CD4+ T cells was 258 
achieved using a modified version of the HIV-1-based lentiviral vector pHRSIREN-S-SBP-259 
∆LNGFR-W42 where the selectable marker for antibody-free magnetic cell sorting sequence (SBP-260 
∆LNGFR) was replaced by the E2-Crimson fluorescent reporter gene for flow cytometry analysis, 261 
generating the pHRSIREN-S-E2-W vector. The shRNA targeting sequence for TRIM5α43 262 
(shTRIM5) was 5′-TGGCTTCTGGAATCCTGGTTAA-3′ and the scrambled shRNA sequence42 263 
(shControl) used as negative control was 5′-GTTATAGGCTCGCAAAAGG-3′. Lentiviral vectors 264 
were produced by co-transfection of 293T cells with p8.91, VSV-G and the pHRSIREN-S-E2-W 265 
vectors at a ratio of 1:0.5:1.5, respectively. Lentiviral particles were concentrated by 266 
ultracentrifugation prior to use for transduction of primary human CD4+ T cells at 2000 x g for 2 267 
h. 48 h after transduction, E2-crimson-positive cells were sorted by flow cytometry (typically 268 
>90%) and cultured in fresh medium. When indicated, 2.5 x 104 cells per well in 96-well plates 269 
were treated with IFNa (2000 U ml-1) for 24 h before infection with NL4-3/Nef-IRES-Renilla (30 270 
ng p24Gag) at 2000 x g for 2 h and infectivity was measured 48 h after infection by measuring 271 
Renilla activity. 272 
 273 
Quantification of mRNA expression. 106 activated primary human CD4+ T cells were collected 274 
with or without 24 h treatment with IFNa, and total RNA was extracted using the RNeasy Mini 275 
Kit (Qiagen). cDNA was generated using 500 ng RNA and the High-Capacity cDNA Reverse 276 
Transcription Kit (ThermoFisher) and qPCR of selected genes was performed using the following 277 
TaqMan gene expression assays (ThermoFisher): TRIM5α (Hs01552559_m1), MX2 278 
(Hs01550808_m1) and GAPDH (Hs99999905_m1). Expression levels of target genes were 279 
normalized to GAPDH. 280 
 281 
Measurement of HIV-1 reverse transcription products. 105 U87-MG CD4+ CXCR4+ were 282 
reverse transfected with 10 nM of a smartpool siRNA targeting human TRIM5α or a non-targeting 283 
siRNA (Dharmacon). Cells were treated with or without 500 U ml-1 IFNa and transfected again 284 
12 h after treatment. 24 h after IFNa treatment, cells were challenged with NL4-3/Nef-IRES-GFP 285 
(20 ng p24Gag) for 2 h and 48 h after infection, cells were collected and total DNA extraction was 286 
performed using the DNeasy kit (Qiagen). Strong-stop cDNA products were detected using 287 
primers that amplify the regions between nucleotides 500 and 635 of the provirus: oHC64, (5’-288 
TAACTAGGGAACCCACTGC) and oHC65 (5’-GCTAGAGATTTTCCACACTG) with probe 289 
oHC66 (5’-FAM-ACACAACAGACGGGCACACACTA-TAMRA), where FAM is 6-290 
carboxyfluorescein and TAMRA is 6-carboxytetramethylrhodamine. qPCR reactions were 291 
performed in triplicate using TaqMan Universal PCR master mix, 900 nM of each primer, and 250 292 
nM of probe. After 10 min at 95 °C, reactions were cycled through 15 s at 95 °C, followed by 1 293 
min at 60 °C for 40 repeats, carried out using the QuantStudio 5 Real-Time PCR System (Applied 294 
Biosystems). NL4-3/Nef-IRES-GFP plasmid was diluted in salmon sperm DNA solution (20 ng 295 
ml-1) to create dilution standards to calculate relative cDNA copy numbers and confirm the 296 
linearity of the assays. 297 
 298 
siRNA mediated knock-down. U87-MG CD4+ CXCR4+ cells were plated at 1.2 x 104 per well 299 
in a 96-well plate and were reverse transfected with 10 nM of smartpool siRNAs (Dharmacon) 300 
targeting TRIM5α (M-007100-00-0005), PSMB8 (M-006022-01-0005), PSMB9 (M-006023-02-301 
0005), PSMB10 (M-006019-01-0005), PA28A (M-012254-00-0005), PA28B (M-011370-00-302 
0005) or individual siRNAs targeting TRIM5α (D-007100-01-0002, D-007100-02-0002, D-303 
007100-03-0002, D-007100-04-0002). A non-targeting siRNA (D-001210-03-05) was used as a 304 
negative control. 24 h after the first transfection, cells were treated with or without IFNa (500 U 305 
ml-1) and a second siRNA transfection was performed 12 h after treatment. 24 h after IFNa 306 
treatment, cells were challenged with the indicated viruses and infectivity was determined 48 h 307 
later. To confirm knock-down efficiency, cell lysates were harvested 24 h after IFNa treatment 308 
and were subjected to SDS-PAGE and immunoblot assays.  309 
 310 
Immunoblotting. Cells were washed with PBS, lysed in sample buffer, boiled for 3 min, resolved 311 
by SDS-PAGE and analyzed by immunoblotting using primary antibodies specific for human 312 
MX2 (sc-47197 (N-17), Santa Cruz Biotechnology), human TRIM5α (ab4389, Abcam), human 313 
PSMB8 (ab3329, Abcam), human PSMB9 (ab3328, Abcam), human PSMB10 (ab77735, Abcam), 314 
human PA28A (ab155091, Abcam), human PA28B (ab183727, Abcam), FLAG (HRP-conjugated 315 
M2, Sigma), HA (HRP-conjugated 3F10, Sigma) or human α-tubulin (DM1A, Sigma), and 316 
detected using either horseradish peroxidase-conjugated secondary antibodies and 317 
chemiluminescence (ECL+ western blotting substrate, Pierce) or IRDye®-800CW-labelled 318 
secondary antibodies and the LI-COR infrared imaging technology (LI-COR UK LTD). 319 
 320 
Immunoprecipitation 3 x 106 U87-MG CD4+ CXCR4+ cells were seeded in 10 cm tissue culture 321 
plates and transfected with the indicated plasmids expressing FLAG-TRIM5α and/or HA-ubiquitin 322 
at a ratio of 1:0.5, using TransIT-2020 transfection reagent according to manufacturer’s 323 
instructions. After 24 h, indicated cells were treated with fresh medium containing or not IFNa 324 
(500 U ml-1) and DMSO, MG132 (0.2 µM) or ONX-0914 (1 µM). 24 h after treatment, cells were 325 
washed twice with PBS, harvested with lysis buffer (1x PBS, 0.5% Triton X-100 and protease 326 
inhibitor cocktail (Roche)) and disrupted by brief sonication. Lysates were cleared by 327 
centrifugation at 10000 × g for 10 min at 4 °C and FLAG-TRIM5α was immunoprecipitated using 328 
anti-FLAG M2 magnetic beads (M8823-5ML, Sigma) for 2 h at 4 °C and the beads washed a 329 
further 4 times in lysis buffer before adding sample buffer (200 mM Tris-HCl pH 6.8, 5.2% SDS, 330 
20% glycerol, 0.1% bromophenol blue, 5% β-mercaptoethanol). HA-tagged proteins 331 
(ubiquitinated proteins) were resolved by SDS-PAGE and detected by immunoblotting using 332 
HRP-conjugated anti-HA antibodies. 333 
 334 
S35 pulse-chase labelling and radio-immunoprecipitation. U87-MG CD4+ CXCR4+ cells were 335 
seeded at 2 x 105 per well in 6-well plates and transfected with pFLAG-TRIM5α using TransIT-336 
2020 transfection reagent according to the manufacturer’s instructions. After 24 h, indicated cells 337 
were treated with fresh medium containing or not IFNa (500 U ml-1). 24 h later, cells were washed 338 
twice with PBS and incubated for 20 min in cysteine/methionine depleted DMEM (Gibco) at 37°C. 339 
The medium was replaced by depletion medium containing 0.25 mCi ml-1 S35-labelled 340 
cysteine/methionine and the cells maintained for 10 min at 37°C. Cells were then washed twice 341 
with PBS and incubated in DMEM. The cells were harvested at various times with lysis buffer (1x 342 
PBS, 0.5% Triton X-100 and protease inhibitor cocktail), incubated on ice for 10 min and clarified 343 
by centrifugation at 10000 × g for 10 min at 4 °C. FLAG-TRIM5α was immunoprecipitated using 344 
anti-FLAG M2 magnetic beads, resolved by SDS-PAGE and exposed on a phosphor image screen 345 
over several days before development on a Typhoon Trio phosphorimager (GE Healthcare). 346 
 347 
Statistical analysis. Results in bar charts are expressed as means ± standard deviation (s.d.) for 348 
experimental replicates in each case. Differences between the experimental groups were evaluated, 349 
where indicated, by paired or unpaired two-tailed t-tests. 350 
 351 
Data availability. The data that support the findings of this study are available from the 352 
corresponding author upon request. 353 
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Figure 1. Human TRIM5a is a key effector in the interferon-induced suppression of HIV-1 476 
infection. a, Dot plots of NL4-3/Nef-IRES-Renilla infectivity and IFNa-induced fold inhibition 477 
at 48 h post-infection in U87-MG CD4+ CXCR4+ cells doubly transfected with siRNAs targeting 478 
598 ISGs and 2 negative controls with or without the addition of 500 U ml-1 IFNα for 24 h. Three 479 
notably influential ISGs are indicated in red. b, Percentage of GFP-positive cells and IFNa-480 
induced fold inhibition in U87-MG CD4+ CXCR4+ cells infected with NL4-3/Nef-IRES-GFP after 481 
TRIM5α silencing using SMARTpool (n = 5) or individual siRNAs (n = 4) with or without added 482 
500 U ml-1 IFNα. c, Immunoblot analysis of TRIM5α expression in U87-MG CD4+ CXCR4+ cells 483 
after siRNA transfection, α-tubulin served as a loading control. One representative immunoblot 484 
from two independent experiments is shown. d, NL4-3/Nef-IRES-GFP infection and IFNa-485 
induced inhibition in U87-MG CD4+ CXCR4+ bulk [TRIM5α (n = 14)] and clonal [TRIM5α #1 486 
(n = 8) and #2 (n = 7)] cell lines transduced to express TRIM5α specific guide RNAs, with or 487 
without added 500 U ml-1 IFNα. CRISPR/Cas9 control cells expressed an unrelated guide RNA (n 488 
= 14). e, Ablation of TRIM5α expression in CRISPR/Cas9 engineered U87-MG CD4+ CXCR4+ 489 
cells was verified by immunoblotting, α-tubulin served as a loading control. One representative 490 
immunoblot from three independent experiments is shown. f, NL4-3/Nef-IRES-GFP infectivity 491 
and IFNa-induced inhibition at 48 h post-infection in TRIM5α deficient U87-MG CD4+ CXCR4+ 492 
cells (CRISPR TRIM5α, TRIM5α #1 and TRIM5α #2) or cells expressing an unrelated guide RNA 493 
(CRISPR control) transduced with EasiLV lentivirus vectors expressing luciferase (Luc) or a 494 
CRISPR-resistant TRIM5α (rTRIM5α) with or without added 500 U ml-1 IFNα (n = 3). g, NL4-495 
3/Nef-IRES-Renilla infectivity and IFNa-induced inhibition at 48 h post-infection in primary 496 
human CD4+ T cells transduced with shRNAs targeting TRIM5α or a control shRNA, and treated 497 
with or without 2000 U ml-1 IFNα for 24 h prior to infection (n = 5). h, U87-MG CD4+ CXCR4+ 498 
cells were transfected with control or TRIM5α-specific siRNAs and treated or not with 500 U ml-499 
1 IFNα for 24 h before 2 h infections with NL4-3/Nef-IRES-GFP (corresponding to 20 ng p24Gag). 500 
DNA was harvested at 48 h post-infection and early reverse transcription products (strong stop) 501 
and IFNa-induced inhibition were determined by qPCR (n = 5). Data are represented as the 502 
mean ± s.d. P values (95% confidence interval) were determined using two-sided, unpaired (b, d, 503 
f and h) or paired (g) t-tests.  504 
Figure 2. HIV-1 Capsid determines IFNa-induced restriction by human TRIM5α. a, 505 
Percentage of GFP-positive cells and IFNa-induced inhibition at 48 h post-infection in U87-MG 506 
CD4+ CXCR4+ cells challenged with GFP-encoding HIV-1-based vectors containing wild-type 507 
CA (WTCA) or CA from SIVMAC (SIVCA). TRIM5α was silenced using SMARTpool siRNAs and 508 
cells treated with or without 500 U ml-1 IFNα before infection (n = 5).  P values (95% confidence 509 
interval) were determined using two-sided, unpaired t-tests. b, NL4-3/Nef-IRES-GFP infectivity 510 
and IFNa-induced inhibition at 48 h post-infection in TRIM5α/MX2 doubly deficient U87-MG 511 
CD4+ CXCR4+ cells (Supplementary Fig. 7) transduced with EasiLV lentivirus vectors expressing 512 
luciferase, CD8, CRISPR-resistant MX2, TRIMCYP or CRISPR-resistant TRIM5α, 513 
TRIM5αΔSPRY, TRIM5α R332G/R335G or TRIM5α H43Y with or without added 500 U ml-1 514 
IFNα (n = 6). Numbers represent fold inhibition of HIV-1 infection after IFNα treatment. Data are 515 
represented as the mean ± s.d. 516 
  517 
Figure 3. HIV-1 restriction by human TRIM5α requires a functional proteasome system. a, 518 
U87-MG CD4+ CXCR4+ cells were co-transfected with a vector expressing HA-ubiquitin37 and 519 
pFLAG-TRIM5α or a control and treated with or without 500 U ml-1 IFNα for 24 h in presence of 520 
DMSO (negative control), the proteasome inhibitor MG132 (0.2 µM), or the immunoproteasome 521 
inhibitor ONX-9014 (1 µM). Whole cell lysates and immunoprecipitated TRIM5α were analyzed 522 
by immunoblotting using an anti-HA (ubiquitin) antibody. One representative immunoblot from 523 
three independent experiments is shown. b, U87-MG CD4+ CXCR4+ cells were co-transfected 524 
with pFLAG-TRIM5α and pFLAG-GFP. 24 h after transfection, cells were treated with or without 525 
500 U ml-1 IFNα for 24 h in the presence of DMSO (n = 6), MG132 (n = 6) or ONX-0914 (n = 5), 526 
lysed and analyzed by immunoblotting using antibodies specific for TRIM5α or FLAG. α-tubulin 527 
served as a loading control. The bar graphs represent the relative band intensities for each protein 528 
normalized to α-tubulin. c, U87-MG CD4+ CXCR4+ cells were cultured with or without 500 U ml-529 
1 IFNα, then for with DMSO (n = 8), MG132 (n = 4 without IFNα and n = 8 with IFNα) or ONX-530 
9014 (n = 4 without IFNα and n = 7 with IFNα) for 24 h and endogenous TRIM5α levels were 531 
determined by immunoblotting. α-tubulin served as a loading control. The bar graph represents the 532 
relative band intensities for TRIM5α normalized to α-tubulin. d, NL4-3/Nef-IRES-GFP infectivity 533 
and IFNa-induced inhibition at 48 h post-infection in U87-MG CD4+ CXCR4+ cells with or 534 
without added 500 U ml-1 IFNα for 24 h before infection in the presence of DMSO, MG132, or 535 
ONX-0914 (n = 4). e, NL4-3/Nef-IRES-GFP infectivity and IFNa-induced inhibition at 48 h post-536 
infection in U87-MG CD4+ CXCR4+ cells expressing an unrelated guide RNA (CRISPR control) 537 
or specific guide RNAs targeting TRIM5α (CRISPR TRIM5α; bulk Figure 1d) treated with or 538 
without 500 U ml-1 IFNα in the presence of DMSO, MG132 or ONX-0914 prior to infection (n = 539 
5). Data are represented as the mean ± s.d. P values (95% confidence interval) were determined 540 
using two-sided, unpaired t-tests. 541 
  542 
Figure 4. HIV-1 restriction by human TRIM5α is regulated by the immunoproteasome. a, 543 
Upon IFNa stimulation, the catalytic subunits (β1, β2, and β3) of the constitutive proteasome are 544 
replaced by inducible catalytic subunits (β1i, β2i and β5i) and expression of the proteasome 545 
activator PA28 subunits A and B is induced. b, Protein levels of immunoproteasome components 546 
and PA28 subunits in U87-MG CD4+ CXCR4+ cells after siRNA transfection with or without 500 547 
U ml-1 IFNα were determined by immunoblotting. α-tubulin served as a loading control. 548 
Immunoblot analysis of the panel was performed once in entirety. c, NL4-3/Nef-IRES-GFP 549 
infectivity and IFNa-induced inhibition at 48 h post-infection in U87-MG CD4+ CXCR4+ cells 550 
after siRNA-mediated silencing of the indicated genes with or without addition of 500 U ml-1 IFNα 551 
24 h before infection (n = 3). d, NL4-3/Nef-IRES-GFP infectivity and IFNa-induced inhibition at 552 
48 h post-infection after siRNA-mediated silencing of PA28A or TRIM5α in U87-MG CD4+ 553 
CXCR4+ cells expressing an unrelated guide RNA (CRISPR control) or specific guide targeting 554 
TRIM5α (CRISPR TRIM5α). 500 U ml-1 IFNα was added for 24 h before infection (n = 9). 555 
Numbers represent changes in the folds of inhibition. Data are represented as the mean ± s.d. P 556 
values (95% confidence interval) were determined using two-sided, unpaired t-tests. 557 
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